Share

July 2021; 8 (4) EditorialOpen Access

The Pursuit of Precision in Paraneoplastic Neurologic Disease

Justin R. Abbatemarco, Stacey L. Clardy
First published May 13, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001015
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
525

Share

Article Information

vol. 8 no. 4 e1015
DOI: 
https://doi.org/10.1212/NXI.0000000000001015
PubMed: 
33986129
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 19, 2021
  • Accepted in final form April 14, 2021
  • First Published May 13, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Justin R. Abbatemarco, MD (justin.abbatemarco@hsc.utah.edu) and
    2. Stacey L. Clardy, MD PhD
  1. Justin R. Abbatemarco, MD (justin.abbatemarco@hsc.utah.edu) and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stacey L. Clardy, MD PhD
    3. Scientific Advisory Boards:

    1. Consulting/Ad Board: Alexion, VielaBio, Genentech, Guidepoint, ExpertConnect, Clarion Healthcare Consulting. (*Majority Fees to U.Utah Development account)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Section Editor, Neurology Podcast (July 2018-present) and Neurology Minute (March 2019-present)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting/Ad Board: Alexion, VielaBio, Genentech, Guidepoint, ExpertConnect, Clarion Healthcare Consulting. (*Majority Fees to U.Utah Development account).

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research Support: Alexion, VielaBio. Site investigator: Alexion clinical trial for Eculizumab in Relapsing NMO patients (in extension).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Research Support: The Siegel Rare Neuroimmune Association (SRNA), the Barbara Gural Steinmetz Foundation, the Sumaira Foundation for NMO.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (J.R.A., S.L.C.), University of Utah; and George E. Wahlen Veterans Affairs Medical Center (S.L.C.), Salt Lake City, UT.
  1. Correspondence
    Dr. Clardy stacey.clardy{at}hsc.utah.edu
View Full Text

Article usage

Article usage: May 2021 to January 2023

AbstractFullPdfSource
May 2021034380Highwire
Jun 2021214628Highwire
Jul 2021031689Highwire
Aug 202129944Highwire
Sep 202106832Highwire
Oct 202115334Highwire
Nov 202114726Highwire
Dec 202114314Highwire
Jan 20227386Highwire
Feb 20221236Highwire
Mar 202204120Highwire
Apr 202213413Highwire
May 202213922Highwire
Jun 202213012Highwire
Jul 202203417Highwire
Aug 20221447Highwire
Sep 202204314Highwire
Oct 202203914Highwire
Nov 202206328Highwire
Dec 20220338Highwire
Jan 202304111Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me